Loading company…
Cambridge, Massachusetts-based developer of T cell therapies for cancer, built on its TRuC platform, which does not require HLA matching.
TCR2 Therapeutics Inc. develops therapies that engage T cells to treat cancer. Its TRuC Platform is a T cell therapy platform that uses the complete T cell receptor complex without the need for human leukocyte antigen matching. Founded in 2015 and based in Cambridge, US, the company is at the Series B stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in